KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500) (80 mg Vial) Dosage Protocol
KLOW combines GHK-Cu (50 mg), KPV (10 mg), BPC-157 (10 mg), and TB-500 (10 mg) in a single 80 mg vial — adding anti-inflammatory KPV to the GLOW formula for immune-modulating regenerative coverage.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)
This multi-peptide blend provides synergistic regenerative, anti-inflammatory, and tissue-repair support. The following titration schedule allows gradual introduction of each component.
| Week | Daily Dose (per component) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to maintain measurable volumes. For ≤10-unit (≤0.10 mL) administrations during initial weeks, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Syringe Math Reference
With 3.0 mL reconstitution volume and 80 mg total peptide:
- Total concentration: 26.67 mg/mL (26,667 mcg/mL)
- TB-500: 3.33 mg/mL → 33.3 mcg per unit
- BPC-157: 3.33 mg/mL → 33.3 mcg per unit
- KPV: 3.33 mg/mL → 33.3 mcg per unit
- GHK-Cu: 16.67 mg/mL → 166.7 mcg per unit
- 1 unit (0.01 mL) = 33.3 mcg each of TB-500, BPC-157, KPV + 166.7 mcg GHK-Cu
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (KLOW, 80 mg each) | 8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 5 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes |
Protocol Overview
KLOW adds KPV's anti-inflammatory action to the GLOW formula. Most useful in protocols where systemic inflammation is contributing to the tissue dysfunction (e.g., chronic gut conditions affecting skin).
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
KLOW adds KPV (α-MSH C-terminal anti-inflammatory tripeptide) to GLOW, providing broad anti-inflammatory coverage alongside skin and tissue repair signaling.
Potential Benefits & Side Effects
Potential Benefits
- All GLOW benefits plus systemic anti-inflammatory action.
- Useful in protocols where inflammation is driving tissue dysfunction.
Side Effect Profile
- Combined profile of components.
- Injection-site reactions.
Lifestyle Factors
- Anti-inflammatory diet supports outcomes.
- Sun protection during dermal repair.
Injection Technique
- Subcutaneous, rotate sites daily.